Department of Pharmacy, Independent University Bangladesh, Dhaka, Bangladesh.
Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh.
Front Immunol. 2024 Feb 29;15:1362780. doi: 10.3389/fimmu.2024.1362780. eCollection 2024.
Dengue, caused by the dengue virus (DENV), affects millions of people worldwide every year. This virus has two distinct life cycles, one in the human and another in the mosquito, and both cycles are crucial to be controlled. To control the vector of DENV, the mosquito , scientists employed many techniques, which were later proved ineffective and harmful in many ways. Consequently, the attention shifted to the development of a vaccine; researchers have targeted the E protein, a surface protein of the virus and the NS1 protein, an extracellular protein. There are several types of vaccines developed so far, such as live attenuated vaccines, recombinant subunit vaccines, inactivated virus vaccines, viral vectored vaccines, DNA vaccines, and mRNA vaccines. Along with these, scientists are exploring new strategies of developing improved version of the vaccine by employing recombinant DNA plasmid against NS1 and also aiming to prevent the infection by blocking the DENV life cycle inside the mosquitoes. Here, we discussed the aspects of research in the field of vaccines until now and identified some prospects for future vaccine developments.
登革热是由登革病毒(DENV)引起的,每年在全球范围内影响数百万人。该病毒有两个明显的生命周期,一个在人类体内,另一个在蚊子体内,这两个周期都需要得到控制。为了控制登革热病毒的传播媒介蚊子,科学家们采用了许多技术,但后来这些技术被证明在许多方面是无效和有害的。因此,人们的注意力转向了疫苗的开发;研究人员将目标对准了病毒的表面蛋白 E 蛋白和细胞外蛋白 NS1 蛋白。到目前为止,已经开发出了几种类型的疫苗,如减毒活疫苗、重组亚单位疫苗、灭活病毒疫苗、病毒载体疫苗、DNA 疫苗和 mRNA 疫苗。除此之外,科学家们还通过使用针对 NS1 的重组 DNA 质粒来探索开发改良疫苗的新策略,旨在通过阻止蚊子体内的登革热病毒生命周期来预防感染。在这里,我们讨论了迄今为止疫苗领域的研究方面,并确定了未来疫苗开发的一些前景。